Quidel Ortho Corp QDEL
We take great care to ensure that the data presented and summarized in this overview for QuidelOrtho Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding QDEL
View all-
T. Rowe Price Investment Management, Inc. Baltimore, MD11MShares$235 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.64MShares$163 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.89MShares$104 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY4.64MShares$99 Million2.25% of portfolio
-
Invesco Ltd. Atlanta, GA2.91MShares$62 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.86MShares$61 Million0.02% of portfolio
-
Newtyn Management, LLC New York, NY2.7MShares$57.6 Million13.3% of portfolio
-
State Street Corp Boston, MA2.67MShares$57 Million0.0% of portfolio
-
American Century Companies Inc Kansas City, MO2.12MShares$45.1 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA1.66MShares$35.5 Million0.0% of portfolio
Latest Institutional Activity in QDEL
Top Purchases
Top Sells
About QDEL
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
Insider Transactions at QDEL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 26
2025
|
Joseph D Wilkins Jr. Director |
BUY
Open market or private purchase
|
Direct |
370
+3.02%
|
$9,990
$27.95 P/Share
|
|
Nov 25
2025
|
Kenneth J Widder Director |
SELL
Open market or private sale
|
Direct |
4,026
-9.8%
|
$108,702
$27.81 P/Share
|
|
Nov 25
2025
|
Kenneth J Widder Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,021
+14.59%
|
$105,315
$15.74 P/Share
|
|
Nov 24
2025
|
Joseph M Busky Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
4,770
+40.8%
|
$124,020
$26.06 P/Share
|
|
Nov 21
2025
|
Mary Lake Ph D Polan Director |
BUY
Open market or private purchase
|
Direct |
1,000
+7.33%
|
$22,000
$22.43 P/Share
|
|
Nov 19
2025
|
Brian J Blaser President and CEO |
BUY
Open market or private purchase
|
Indirect |
23,500
+44.31%
|
$493,500
$21.34 P/Share
|
|
Nov 18
2025
|
Michelle A. Hodges Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,717
-7.82%
|
$57,057
$21.28 P/Share
|
|
Nov 18
2025
|
Michelle A. Hodges Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,349
+13.34%
|
-
|
|
Oct 15
2025
|
Jonathan Philip Siegrist EVP of R&D & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,676
-35.78%
|
$180,252
$27.31 P/Share
|
|
Oct 15
2025
|
Jonathan Philip Siegrist EVP of R&D & CTO |
BUY
Grant, award, or other acquisition
|
Direct |
18,656
+50.0%
|
-
|
|
Oct 15
2025
|
Michelle A. Hodges Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
199
-0.67%
|
$5,373
$27.31 P/Share
|
|
Oct 15
2025
|
Michelle A. Hodges Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
390
+1.3%
|
-
|
|
Sep 15
2025
|
Ronald Lee Bowman Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
918
-35.79%
|
$25,704
$28.92 P/Share
|
|
Sep 15
2025
|
Ronald Lee Bowman Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,565
+50.0%
|
-
|
|
Jul 15
2025
|
Kenneth F Buechler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,215
+8.29%
|
$138,225
$15.74 P/Share
|
|
Jun 30
2025
|
Michelle A. Hodges Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,030
-17.11%
|
$168,840
$28.82 P/Share
|
|
Jun 30
2025
|
Michelle A. Hodges Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,873
+25.2%
|
-
|
|
Jun 30
2025
|
Philip D. Mc Lellan Chief Operations Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,951
-12.79%
|
$54,628
$28.82 P/Share
|
|
Jun 30
2025
|
Philip D. Mc Lellan Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,749
+23.74%
|
-
|
|
Jun 30
2025
|
Joseph M Busky Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,883
-23.92%
|
$276,724
$28.82 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 169K shares |
|---|---|
| Open market or private purchase | 35.7K shares |
| Exercise of conversion of derivative security | 16.2K shares |
| Payment of exercise price or tax liability | 50.6K shares |
|---|---|
| Open market or private sale | 4.03K shares |